Your browser doesn't support javascript.
loading
An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score.
Reddy, Yogesh N V; Carter, Rickey E; Sundaram, Varun; Kaye, David M; Handoko, M Louis; Tedford, Ryan J; Andersen, Mads J; Sharma, Kavita; Obokata, Masaru; Verbrugge, Frederik H; Borlaug, Barry A.
Afiliação
  • Reddy YNV; The Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
  • Carter RE; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
  • Sundaram V; Department of Cardiology, Louis Stokes Cleveland Department of Veteran Affairs, Case Western Reserve University, Cleveland, OH, USA.
  • Kaye DM; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Handoko ML; Departments of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, the Netherlands.
  • Tedford RJ; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
  • Andersen MJ; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Sharma K; Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Obokata M; Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Verbrugge FH; Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
  • Borlaug BA; Centre for Cardiovascular Diseases, University Hospital Brussels, Brussels, Belgium.
Nat Med ; 2024 Jul 12.
Article em En | MEDLINE | ID: mdl-38997608
ABSTRACT
Heart failure with preserved ejection fraction (HFpEF) is under-recognized in clinical practice. Although a previously developed risk score, termed H2FPEF, can be used to estimate HFpEF probability, this score requires imaging data, which is often unavailable. Here we sought to develop an HFpEF screening model that is based exclusively on clinical variables and that can guide the need for echocardiography and further testing. In a derivation cohort (n = 414, 249 women), a clinical model using age, body mass index and history of atrial fibrillation (termed the HFpEF-ABA score) showed good discrimination (area under the curve (AUC) = 0.839 (95% confidence interval (CI) = 0.800-0.877), P < 0.0001). The performance of the model was validated in an international, multicenter cohort (n = 736, 443 women; AUC = 0.813 (95% CI = 0.779-0.847), P < 0.0001) and further validated in two additional cohorts a cohort including patients with unexplained dyspnea (n = 228, 136 women; AUC = 0.840 (95% CI = 0.782-0.900), P < 0.0001) and a cohort for which HF hospitalization was used instead of hemodynamics to establish an HFpEF diagnosis (n = 456, 272 women; AUC = 0.929 (95% CI = 0.909-0.948), P < 0.0001). Model-based probabilities were also associated with increased risk of HF hospitalization or death among patients from the Mayo Clinic (n = 790) and a US national cohort across the Veteran Affairs health system (n = 3076, 110 women). Using the HFpEF-ABA score, rapid and efficient screening for risk of undiagnosed HFpEF can be performed in patients with dyspnea using only age, body mass index and history of atrial fibrillation.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article